^
Association details:
| Biomarker: | LMNA-NTRK1 rearrangement |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Excerpt:
A patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement displayed a remarkable response to treatment with entrectinib, which was followed by the emergence of resistance.
DOI:
10.1158/2159-8290.CD-15-0940
